As shown in Figures 3C–Q, inhibition of c-JUN alone had a non-significant anti-HCC effect but enhanced tumor sensitivity to JSH-23 compared to that in the vehicle-treated control, leading to an overall significant synergistic effect through reducing tumor mass by 79% (from 39.29 to 8.13) and disseminated tumor foci by 96% (from 44.90 to 1.80) when combined with JSH-23. This evidence concerns the gene JUN and hepatocellular carcinoma.